Search
Solid Biosciences Inc
SLDBAdd to Watchlist
8.050USD
-0.440-5.18%
Close 07-31 16:00（ET）Quotes delayed by 15 min
792.08MMarket Cap
LossP/E TTM
More Details of Solid Biosciences Inc Company
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Solid Biosciences Inc Info
Ticker SymbolSLDB
Company nameSolid Biosciences Inc
IPO dateJan 26, 2018
CEOCumbo (Alexander)
Number of employees100
Security typeOrdinary Share
Fiscal year-endJan 26
Address500 Rutherford Avenue
CityCHARLESTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02129
Phone16173374680
Websitehttps://www.solidbio.com/
Ticker SymbolSLDB
IPO dateJan 26, 2018
CEOCumbo (Alexander)
Company Executives of Solid Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.41K
+1.22%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
146.16K
+8.65%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
141.59K
+2.43%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
105.08K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
82.81K
-43.95%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
74.32K
-46.95%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
63.78K
-52.65%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.41K
+1.22%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
146.16K
+8.65%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
141.59K
+2.43%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
105.08K
--
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
82.81K
-43.95%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
74.32K
-46.95%
FAQs
Who are the top five shareholders of Solid Biosciences Inc?
The top five shareholders of Solid Biosciences Inc are: Mr. Alexander (Bo) Cumbo
How many institutions hold shares of Solid Biosciences Inc (SLDB)?
As of 2026Q1, 271 institutions hold shares of Solid Biosciences Inc, with a combined market value of approximately 83.89M, accounting for 85.25% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -13751546.00.